Table 3.
Individual and combined diagnostic performance of anti-phospholipid (aPL) antibody assays.
| Assays | Sensitivity (95% CI)*, % | Specificity (95% CI)*, % | PPV (95% CI)*, % | NPV (95% CI)*, % |
|---|---|---|---|---|
| APS group | ||||
| aCL | 83·8 (72·4–92·0) | 87·8 (78·2–94·2) | 85·2 (73·8–93·0) | 86·6(76·8–93·4) |
| aβ2GPI | 69·4 (56·4–80·4) | 96·0 (88·6–99·2) | 93·4 (82·2–98·6) | 78·8 (69·0–86·8) |
| aCL and β2GPI | 87·0 (76·2–94·2) | 85·2 (75·0–92·4) | 83·0 (71·8–91·2) | 88·8 (79·0–95·0) |
| aPL Aesku | 92·0 (82·2–97·4) | 70·2 (61·0–81·6) | 72·2 (61·0–81·6) | 91·2 (80·8–97·0) |
| RPL group | ||||
| aCL | 3·0 (0·4–10·6)† | 87·8 (78·2–94·2) | 18·2 (2·2–51·8)‡ | 50·4 (41·4–59·4) |
| aβ2GPI | 4·6 (1·0–12·8)† | 96·0 (88·6–99·2) | 50·0 (11·8–88·2) | 53·0 (44·2–61·6) |
| aCL and β2GPI | 6·0 (1·6–14·8)† | 85·2 (75·0–92·4) | 26·6 (7·8–55·2)‡ | 50·4 (41·4–59·4) |
| aPL Aesku | 39·4 (27·6–52·2)† | 70·2 (58·6–80·4) | 54·2 (39·2–68·6)‡ | 56·6 (45·8–66·8) |
95% CI for the calculated individual and combined sensitivities, specificities, positive predictive values (PPVs) and negative predictive values (NPV) for the recommended (without LA) and all non-recommended aPL assays in the anti-phospholipid syndrome (APS) or recurrent pregnancy loss (RPL) groups compared with the healthy blood donor (HBD) and women with histories of successful pregnancies (WSP) controls.
Denotes significant differences (P < 0·05) between the sensitivities of aCL or anti-beta-2 glycoprotein I (aβ2GPI) or aCL and β2GPI versus all aPL Aesku.
Shows significant differences (P < 0·05) in the PPV between aCL or aCL and β2GPI versus all aPL Aesku (RPL groups only).
CI, confidence interval.